Stay updated on PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.

Latest updates to the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed descriptions of a Phase 3 clinical trial for non-small cell lung cancer and the associated inclusion and exclusion criteria. Additionally, a new revision number has been added.SummaryDifference5%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check92 days agoChange DetectedThe website has updated to revision v2.14.2, noting that some NLM-NCBI services are experiencing heavy traffic, which may impact performance and availability.SummaryDifference0.7%
Stay in the know with updates to PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.